



Press release

## **MEDIAN Technologies Announces a reserved capital increase of €20 Million**

**Investment led by New Enterprise Associates (NEA), a leading US healthcare investor**

- ✓ *Additional leading healthcare investors including Omega Fund Management and Abingworth, other US and UK based funds as well as MEDIAN Technologies' historic investors AURIGA partners, DFJ ePlanet Ventures and IDInvest will take part in the transaction;*
- ✓ *This financing will allow MEDIAN Technologies to accelerate its global growth plans and further enhance its customer offerings.*

**Sophia Antipolis, France – August 25<sup>th</sup> 2014** – MEDIAN Technologies (ALMDT.PA), a leading medical imaging solutions and service provider for image interpretation and management in oncology clinical trials, cancer screening programs and routine practice in oncology, announced that it has obtained commitments from thirteen non-affiliated and affiliated institutional investors to purchase approximately €20.0 million of its common stock in a capital increase without preferential subscription right reserved to institutional investors led by New Enterprise Associates (NEA) pursuant to article L. 225-138 of the French commercial Code. MEDIAN Technologies has entered into a Subscription Agreement with each of the investors pursuant to which MEDIAN Technologies will sell an aggregate of 2,222,222 units at a price of €9.00. Each unit is composed of one share of common stock and one warrant. The new shares will be fungible with MEDIAN's outstanding shares and, upon closing, will represent 36.83% of the share capital of MEDIAN Technologies and will correspond to a dilution of 26.91% for the existing shareholders.

Two warrants shall give the right to subscribe to one share of common stock from the issuance date until the seventh anniversary of their issuance date. The warrants shall be exercisable at €9.00 per full share of common stock. Warrants shall not be listed on the Alternext Market. If all warrants are exercised, the company would receive an additional €10.0 million of proceeds. The subscription undertakings of each of the investors are subject to customary closing conditions for this type of transaction, particularly obtaining the approval of the Extraordinary Shareholders' Meeting of MEDIAN Technologies.

Pursuant to the aforementioned Subscription Agreements, MEDIAN Technologies notably undertakes to authorize and carry out all the operations in relation with the possible listing of the MEDIAN Technologies' shares on the NYSE or Nasdaq regulated market or, failing that, the transfer of the listing of the shares to Euronext Paris.

The financing will be subject to shareholders' approval during the next Extraordinary Shareholders' Meeting on September 29<sup>th</sup> 2014. Founding shareholders as well as major shareholders of MEDIAN Technologies strongly support this transaction, and in this regard, more than two thirds of the



current shareholders have already agreed to vote in favour of the resolutions related to this financing to be presented at this Extraordinary Shareholders' Meeting.

*"We believe that the analytics and software solutions developed by MEDIAN Technologies medical are truly disruptive and has the potential to change the way imaging is used within oncology, leading to a real paradigm shift in the development and assessment of new cancer treatments and in the care of cancer patients" said Dr. Otello Stampacchia, Investment Advisor at Omega Fund Management, who will join the Board of Directors as part of this transaction.*

*"We are proud to have as an investor in MEDIAN Technologies such a prestigious fund as the lead investor NEA, and all the investment funds which are taking part in this transaction. The value added that we provide in oncology imaging, as well as the key differentiators of our product were decisive in achieving this capital increase with highly regarded and knowledgeable investors in our field" emphasized Fredrik Brag, CEO of MEDIAN Technologies. "This financing will support and further accelerate our international expansion, in particular in the North American and Asian markets for which we have great ambitions," he added.*

Cowen and Company, LLC served as placement agent to the Company.

**ALMDT**  
**LISTED**  
**NYSE**  
**ALTERNEXT**

**About MEDIAN Technologies:** MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. MEDIAN Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. MEDIAN serves two primary markets: drug development and patient care. MEDIAN has a strategic partnership with the world's largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, MEDIAN Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.

MEDIAN has received the label "Innovative company" by the BPI and is listed on Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup. For more information on MEDIAN, please visit: [www.mediantechologies.com](http://www.mediantechologies.com)

#### **DISCLAIMER**

*This press release is for information purposes only. According to article 211-3 of the AMF's General Regulation, this capital increase through a private placement has not given and will not give rise to a prospectus approved by the AMF.*

*This press release does not constitute and may not be considered as a public offer, a subscription offer or a solicitation of public interest for a public offering of financial securities nor does it constitute an*



# MEDIAN

*offer to sell or the solicitation of a subscription for, or any offer to buy, any securities in France, The United States or any other jurisdiction. The distribution of this press release in certain countries may constitute a breach of applicable laws and MEDIAN Technologies has not authorized the distribution of this press release in any such country. The securities may not be offered or sold in the United States absent registration of such offer and sale under the U.S. securities act of 1933, as amended or an exemption from such registration, and while no registration or any public offering of the securities is currently planned, any public offering of securities to be made in the United States would have to be made by means of a prospectus that would contain detailed information about the company and its management, as well as MEDIAN Technologies' financial statements.*

**“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”**



## Contacts

### **MEDIAN Technologies**

Fredrik Brag, CEO  
+33 4 92 90 65 82  
fredrik.brag@mediantechnologies.com

### **Press**

**ALIZE RP**  
Caroline Carmagnol  
Valentine Boivin/Sophie Colin  
+ 33 1 70 22 53 93  
median@alizerp.com

### **Investors**

**ACTIFIN**  
Christophe de Lylle  
+ 33 1 56 88 11 11  
cdelylle@actifin.fr